Eli Lilly reported strong third-quarter earnings, exceeding revenue estimates. The company raised its fiscal 2025 outlook to $63-$63.5 billion in revenue and $23-$23.70 per share in profit. Mounjaro brought in $6.52 billion, up 109%, while Zepbound saw $3.59 billion, up 184%. Eli Lilly dominates the GLP-1 drug market.

Eli Lilly CEO Dave Ricks credits tirzepatide for the stellar performance, particularly in international markets like China, Brazil, and India. The company gained share in injectable obesity and diabetes drugs for five consecutive quarters. The third quarter results surpassed Wall Street expectations, with $17.60 billion in revenue and $7.02 EPS.

Eli Lilly posted net income of $5.58 billion for the quarter. The company’s strong performance is attributed to the success of Mounjaro and Zepbound in the U.S. market. Eli Lilly continues to focus on direct-to-consumer sales and expanding cash-pay options for its drugs. The company is preparing for the global rollout of its experimental obesity pill orforglipron.

Read more at CNBC: Eli Lilly (LLY) earnings Q3 2025